The Prevalence of ESBLs Producing Klebsiella pneumoniae Isolates in Some Major Hospitals, Iran by Ghafourian, Sobhan et al.
  The Open Microbiology Journal, 2011, 5, 91-95 91 
 
  1874-2858/11  2011 Bentham Open 
 Open Access 
The Prevalence of ESBLs Producing Klebsiella pneumoniae Isolates in 
Some Major Hospitals, Iran 
Sobhan Ghafourian










5 and Reza Ranjbar
6 
1Department of Medical Microbiology, and Parasitology, Faculty of Medicine and Health Science, University Putra Malaysia 
2Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran 
3Department of Medical Microbiology, Ilam University of Medical Sciences, Ilam, Iran 
4Reference Laboratory of Iran 
5Faculty of Food Science and Technology, University Putra Malaysia, Malaysia 
6Molecular Biology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran 
Abstract: Aims of this study were to investigate on antibiotic resistance and molecular epidemiology of K.pneumoniae 
producing ESBLs isolates of respiratory tract infections in some major hospitals in Iran. K.pneumonaie were obtained  
of patients with RTI. K. pneumoniae producing ESBLs detected by screening, confirming and PCR methods. During the 
12-month period, a total of one hundred and thirteen of K.pneumoniae were found from RTI in three cities in different  
region of Iran which Sixty seven strains (59.2%) were ESBLs producer. In Ilam hospitals, seventeen strains (43.6%),  
in Milad hospital, thirty-seven strains (74%) and in Emam Reza hospital, thirteen strains (54.2%) were ESBLs producer. 
The findings showed that among sixty-seven K.pneumoniae producing ESBLs, Sixty-three strains (94%) were positive  
for  blaSHV, eleven strains (16.4%) contained blaTEM and sixteen strains (23.9%) harbored blaCTX-M. Imipenem   
was found as an effectiveness antibiotic. In the current study, Majority of the ESBLs production had occurred in Milad 
hospital in Tehran (74%). In conclusion, spreading ESBL-producing strains is a concern, as it causes limitations to the  
antimicrobial agents for optimal treatment of patients. 
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INTRODUCTION 
  Extended-spectrum beta-lactamase (ESBL)-producing 
Klebsiella pneumoniae have spread rapidly worldwide and 
pose a serious threat in healthcare-associated infections [1]. 
ESBLs have spread threateningly in many regions of the 
world and now comprise over three hundred variants 
(http://www.lahey.org/studies). 
  ESBLs are plasmid-mediated enzymes that hydrolyze 
broad-spectrum beta-lactams and are strongly inhibited   
by clavulanate. ESBLs are transmitted by plasmids among 
bacteria. Furthermore, antibiotics such as trimethoprim-
sulfamethoxazole, aminoglycosides and fluoroquinolones are 
often co-transferred on a resistance plasmid, resulting in 
multiple drug resistance. Thus clinical treatment failure oc-
curs frequently, especially when inappropriate antimicrobial 
therapy is used to treat infections caused by ESBL- produc-
ing organisms. Therefore, if infections with ESBL-producing 
organisms can be predicted by the clinical characteristics of 
patients, this may lead to a better selection of antibiotics and 
may improve the outcome of infections [2]. 
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  This study was done to investigate on antibiotic resistance 
and molecular epidemiology of K. pneumoniae producing   
ESBLs in patients with respiratory tract infections in some 
major hospitals in Iran. 
MATERIAL & METHODS 
  Sample collection: one hundred and thirteen clinical iso-
lates of K.pneumoniae were identified during Mar. 2007 to  
Apr. 2008 in five hospitals in three Iranian cities (Ilam in 
west of Iran, Tabriz in west north of Iran, and Tehran in   
center and capital of Iran). K. pneumoniae isolates were   
obtained of sputum, tracheal aspirates, bronchial washing 
and bronchoalveolar lavage. Collection of multiple samples 
of the same patient was, however, avoided in the database. 
Screening Stage 
  Kirby-Bauer disk diffusion test by using Mueller-Hinton 
agar diminished zones of inhibition around 3
rd generation 
beta-lactam disks were considered suggestive of ESBL pro-
duction. According to NCCLS (2005) the following antibiot-
ics were used to indicate ESBL production: cefpodoxime (30 
g), cefotaxime (30 g), ceftazidime (30 g), cefteriaxone 
(30 g) and aztreonam (30 g) [3]. 92    The Open Microbiology Journal, 2011, Volume 5  Ghafourian et al. 
Clavulanic Acid Association Test 
  For the combined disk method, disks containing   
cefpodoxime (30 g), ceftazidime (30 g) and cefotaxime 
(30 g) with and without clavulanic acid (10 g), were used. 
The resulting inhibition zones were compared. The test was 
considered positive when the difference of zone diameters 
between the beta-lactam disk and disk containing antibiotic 
associated with clavulanic acid was > 5mm [4]. 
Effect of non Beta-Lactame Antibiotics Against Klebsiella 
pneumoniae 
  Amikacin (Ak) (30ug), cotrimoxazol (Co) (30ug) cipro-
floxacin (Cf) (30ug), imipenem (I) (30ug) were used among 
K.pneumoniae producing ESBLs toward non beta-lactam 
antibiotics [5]. All antibiotic disks were obtained in HiMedia 
Company in India. 
Molecular Methods 
DNA Extraction 
 K.pneumoniae  Producing ESBLs were cultured in LB 
broth at 37°C overnight, and then DNA was extracted by 
using the DNA extraction kit (fermenrtase). 
Polymerase Chain Reaction (PCR) 
  The polymerase chain reaction (PCR) was carried out by 
following primers: blaTEM (Forward 5-GAGTATCAACA 
TTTCCGTGTC-3, Reverse primer 5-TAATCAGTGAGG 
CAC CTTCTC-3), blaSHV (5’–AAGATCCACTATCGCCCA 
GCAG-3, Reverse 5–AAGATCCA CTATCGCCCAGCAG-3) 
[6] and blaCTX-M, (forward 5-ACGCTGTTGTTAGGAA 
GTG-3, reverse 5-TTGAGGCTGGGTGAAGT-3) [7].  
RESULTS 
  During the 12-month period, a total of one hundred and 
thirteen of K.pneumoniae isolates were obtained from respi-
ratory tract infection in three cities in different part of Iran. 
While total of sixty-seven strains (59.2%) produced ESBLs, 
numbers of forty-six strains (40.8%) were non ESBLs pro-
ducer. Generally, amongst ESBLs producer K.pneumoniae, 
all the strains were resistant to aztreonam and cefpodoxime. 
Cefotaxime (68.6%) allocated the lowest resistant among 
third generation of cephalosporin. Imipenem were found as 
an effectiveness antibiotic while resistance to cotrimoxazol 
(35.8%) was more than the others (Table 1). In non ESBLs 
K.pneumoniae strains, no resistance occurred among aztreo-
nam, while the highest resistance observed in cefotaxime and 
ceftazidime (50%). In this study, all the non ESBLs 
K.pneomoniae were susceptible to the whole non-beta lactam 
antibiotics (Table 2). In Ilam city in the west of Iran, thirty-
nine  K.pneumoniae were found that seventeen strains 
(43.6%) were ESBLs producer and twenty-two strains 
(56.4%) were negative for ESBLs production; in Tehran city 
in capital of Iran (Milad hospital), of fifty K.pneumoniae, 
thirty-seven strains (74%) were positive for producing 
ESBLs and thirteen strains (26%) were negative on behalf of 
producing ESBLs and in Tabriz city in the west north of Iran 
(Emam Reza hospital), twenty-four K. pneumoniae obtained 
which thirteen strains (54.2%) were ESBLs producer and 
eleven strains (45.8%) were negative. 
 Among  K.pneumoniae producing ESBLs, 25.4% (n=17), 
55.2% (n=37) and 19.4% (n=13) strains were isolated in Ilam, 
Milad and Emam Reza hospitals, respectively (Table 1). 
  Results revealed that among sixty-seven K.pneumoniae 
producing ESBLs, Sixty-three strains (94%) were positive 
for blaSHV, eleven strains (16.4%) contained blaTEM and 
sixteen strains (23.9%) harbored blaCTX-M. blaCTX-M and 
blaSHV together were present in fourteen strains (20.9%), 
nine strains (13.4%) carried both blaSHV and blaTEM, four 
isolates (6%) were positive for blaTEM and blaCTX-M and 
finaly, four isolates (6%) carried all three blaSHV, blaTEM 
and blaCTX-M. 
  In Milad hospital, all K.pneumoniae producing ESBLs 
were positive for blaSHV, eight strains (21.6%) contained 
Table 1.  Antibiotic Panel of K.pneumoniae Producing ESBLs Strains  
ESBLs Positive 
K.pneumoniae  
In Ilam Hospital 
N=17 
ESBLs Positive K.pneumoniae  
In Emam Reza Hospital 
N=13 
ESBLs Positive K.pneumoniae 
In Milad Hospital 
N=37 




Resistance % Sensitivity%  Resistance % Sensitivity%  Resistance % Sensitivity%  Resistance % Sensitivity% 
Ca  14 (82%) 3 (18%)  13 (100%) 0  35 (94.6%) 2 (5.4%)  62 (92.5%) 5 (7.5%) 
Ce  6 (35.2%) 11 (64.8%)  12(92.3%) 1 (7.7%)  28(75.7%) 9 (24.3%)  46 (68.6%) 21(31.3%) 
Ci  17 (100%) 0  13 (100%) 0  32 (86.5%) 5 (13.5%)  62 (92.5%) 5 (7.5%) 
Cep  17 (100%) 0  13 (100%) 0  37 (100%) 0  67 (100%) 0 
Ao  17 (100%) 0  13 (100%) 0  37 (100%) 0  67 (100%) 0 
Ak  3 (18%) 14 (82%)  3 (23.1%) 10 (76.9%)  13 (35.1%) 24 (64.9%)  19 (28.3%) 48(71.6%) 
Cf  2 (12%) 15 (88%)  1 (7.7%) 12 (92.3%)  8 (21.6%) 29 (78.4%)  11 (16.4%) 56(83.6%) 
Co  7 (41%) 10 (59%)  3 (23.1%) 10 (76.9%)  14 (37.9%) 23 (62.1%)  24 (35.8%) 43(64.1%) 
I  0 17 (100%)  0 13 (100%)  0 37 (100%)  0 67(100%) The Prevalence of ESBLs producing Klebsiella pneumoniae Solates  The Open Microbiology Journal, 2011, Volume 5    93 
blaTEM and ten isolates (27%) carried blaCTX-M. blaSHV 
and  blaCTX-M presented in ten (27%) of strains. Eight 
strains (21.6%) carried both blaSHV and blaTEM. Four iso-
lates were positive for both blaTEM and blaCTX-M and all 
three genes were found in four isolates (10.8%). 
  In Ilam hospital, among seventeen K.pneumoniae pro-
ducing ESBLs, blaSHV was found in thirteen strains 
(76.5%), two strains (11.8%) were positive for blaTEM, and 
blaCTX-M presented in five strains (29.4%). Three strains 
(17.7%) carried both blaSHV and blaCTX-M. 
  In Emam Reza hospital, all strains were positive for 
blaSHV, while one strain carried blaTEM and one isolate 
was positive for blaCTX-M and one for both blaSHV and 
blaCTX-M, as well.  
DISCUSSION 
  The high rate of ESBLs among hospitalized patients is a 
global problem. It is generally thought that patients infected 
by an ESBL-producing organism are at an increased risk of 
treatment failure with an expanded-spectrum beta-lactam. 
The prevalence of ESBL producing isolates of K. pneumo-
niae varies in different countries [8]. 
  Countries with a high rate of prevalence include Turkey 
(60%), Latin America (45.4%), Western Pacific (24.6%), 
and Europe (22.6%) [9]. 
  In this study, ESBLs production was variable from 
43.6% in Ilam hospital to 74% in Milad hospital that showed 
different frequency of ESBLs production in different region 
in Iran. Our study showed significantly high ESBLs production.  
  The prevalence of respiratory isolates of K. pneumoniae 
with ESBL phenotype has been reported from less than 1% 
in Japan [10] to 83.3% in China [11]. 
  We showed that the percentage of respiratory isolates 
with K. pneumoniae was high. Milad hospital contributed to 
more of the K.pneumoniae isolates. The lowest K.pneumoniae 
producing ESBLs had observed in Ilam hospital. Non- 
beta-lactam antibiotic resistance in Milad hospital was more 
than the others. Imipenem was found as an effectiveness 
antibiotic.  
  In this study, susceptibility testing of K.pneumonie 
strains producing ESBLs showed that the highest resistance 
rate among 3
rd generation of cephalosporins and aztreonam 
were cefpodoxime and aztreoname in all hospitals, cefteriax-
one in Emam Reza and Ilam hospitals and ceftazidime in 
Emam Reza hospital. The highest non-beta lactam antibiotic 
resistance occurred in cotrimoxazol in Ilam hospital. 
Imipenem was found as effectiveness antibiotic among 
ESBLs producing K.pneumoniae strains.  
  Majority of the ESBLs production recurred in Milad hos-
pital (74%). The highest resistance toward non-beta-lactam 
antibiotic was observed in cotrimoxazol (41%) in Ilam hos-
pital. The best antibiotics were Imipenem (100%) in all hos-
pitals and following ciprofloxacine (92.3%) in Emam Reza 
Hospital. In non-ESBLs, K.pneumoniae Resistance toward 
cefotaxime (76.9%) was more than the other antibiotics. The 
most genes responsible for ESBLs production were found in 
blaSHV. In Ilam Hospital, frequency of blaCTX-M was 
more than blaTEM. 
  In Milad Hospital, Frequency of blaCTX-M was more 
than blaTEM. 
  Our finding in Emam Reza hospital had showed fre-
quency of blaTEM and blaCTX-M were as an equal. 
  The prevalence of blaSHV,blaTEM and blaCTX-M 
genes in this study was 94%, 16% and 23.9%, respectively. 
  In Iran, Feizabadi et al., in 2009 showed that 69.7% of K. 
pneumoniae isolates in Tehran were ESBL producers and the 
prevalence of blaTEM, blaSHV, blaCTX-M-I and blaCTX-
M-III among these isolates were 54%, 67.4%, 46.51% and 
Table 2.  Antibiotic Panel of K.pneumoniae non-ESBLs Strains  
ESBLs Negative K.pneumoniae 
In Ilam Hospital 
N=22 
ESBLs Negative K.pneumoniae  
In Emam Reza Hospital 
N=11 
ESBLs Negativ K.pneumoniae  
In Milad Hospital 
N=13 




Resistance % Sensitivity%  Resistance % Sensitivity%  Resistance % Sensitivity%  Resistance % Sensitivity% 
Ca  11 (50%) 11 (50%)  6 (54.5%) 5 (45.6%)  6 (46.2%) 7 (53.8%)  23 (50%) 23 (50%) 
Ce  9 (40.9%) 13 (59.1%)  4 (36.3%) 7 (63.7%)  10(76.9%) 3(23.1%)  23 (50%) 23(50%) 
Ci  12 (54.5%) 10 (45.6%)  5 (45.5%) 6 (54.5%)  5 (38.5%) 8 (61.5%)  22 (47.9%) 24 (52.1%) 
Cep  1 (4.5%) 21 (94.5%)  1 (9%) 10 (90.9%)  0 13(100%)  2 (4.34%) 44(95.6%) 
Ao  0 22 (100%)  0 11 (100%)  0 13(100%)  0 46(100%) 
Ak  0 22 (100%)  0 11 (100%)  0 13(100%)  0 46(100%) 
Cf  0 22 (100%)  0 11 (100%)  0 13(100%)  0 46(100%) 
Co  0 22 (100%)  0 11 (100%)  0 13(100%)  0 46(100%) 
I  0 22 (100%)  0 11 (100%)  0 13(100%)  0 46(100%) 94    The Open Microbiology Journal, 2011, Volume 5  Ghafourian et al. 
29%, respectively (12). Our results revealed high prevalence 
of blaSHV and low frequency of blaTEM and blaCTX-M. 
Significantly, blaSHV was more responsible for ESBLs pro-
duction [12]. 
  In the study a tertiary care hospital in Tehran 77% of 
K.pneumoniae were ESBLs producer [13] while in our study 
in Ilam and Emam Reza hospitals frequency of ESBLs pro-
duction were lower while the results of Milad hospital (74%) 
was near to the study of mehregan et al., [13]. In a survey by 
bazzaz et al., in 2007 in general hospital in Iran 59.2% of 
isolates were positive for ESBLs production and all isolates 
were susceptible to imipenem [14], our finding showed all 
strains were susceptible to imipenem. Our findings in Milad 
hospital revealed higher ESBLs production as comparison to 
bazzaz et al., [14]. 
 Shahcheragi  et al., [6] showed that ESBLs production 
observed in 33% of isolates while in our study the lowest 
ESBLs production was presented in Ilam hospital (43.6%). 
All isolates in survey of shahcheraghi et al., [6] were suscep-
tible to imipenem and ciprofloxacine resistance was ob-
served in 32% of K.pneumoniae. our finding revealed all 
strain were susceptible to imipenem but the highest rate of 
resistant to ciprofloxacine was observed in Milad hospital 
and that was 21.6%. In the study of shahcheraghi et al., 
69.6% of strains carried blaSHV and 32.1% of K.pneumonie 
producing ESBLs harbored blaTEM [6] while our results 
showed all strains in Emam Reza and Milad hospitals carried 
blaSHV and this was 76.5% in Ilam hospital (94%). Fre-
quency of blaTEM was lower (16.4%) than survey of 
shahcheraghi et al., in this study we found different ESBLs 
production in different regions of Iran that one of the reason 
may related to population in different city and also Using of 
antibiotic in Iran is uncontrollable, use of antibiotics and 
injectable formulations was high in the Islamic Republic of 
Iran. The high number of prescriptions for antibiotics (58% 
on average) may be because in the majority of the provinces, 
the data collected only covered a period of 1 month. And 
different prescriptions may have result of different resistance 
to antibiotics [15]. In conclusion, spreading ESBL-producing 
strains is a concern, as it causes limitations to the antimicro-
bial agents for optimal treatment of patients. The most reli-
able and effective antimicrobial treatment for infections 
caused by this organism is imipenem
  [16] and also had 
shown in this study. BlaSHV was found as a predominant 
gene responsible for ESBLs production and future study 
need to determine type of bla genes responsible for ESBLs 
producing strains in Iran and more study in different part   
of Iran.  
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ABBREVIATIONS 
Ak =  Amikacin 
Ao =  Aztreonam 
Ca =  Ceftazidim 
Cac =  Ceftazidime/clavulanic 
Ce =  Cefotaxime 
Cec =  Cefotaxime  /clavulanic 
Cep =  Cefpodoxim 
Cepc  =  Cefpodoxim /clavulanic acid 
Cf =  Ciprofloxacin 
Ci =  Cefteriaxon 
Co =  Cotrimoxazol 
ESBL  =  Extended spectrum beta-lactamases 
I =  Imipenem 
K. pneumoniae = Klebsiella pneumoniae 
RTI =  Respiratory  tract  infection 
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